文献速递前列腺癌

在晚期前列腺癌且合并心血管疾病的患者中比较GnRH激动剂与GnRH拮抗剂的心血管疾病发病率的随机试验

Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
PubMed 文献 · J Urol · 2019-06-12

这项II期随机开放标签研究纳入80例合并心血管疾病的前列腺癌患者,随机接受GnRH激动剂或拮抗剂治疗1年。主要终点内皮功能两组无差异(反应性充血指数2.07±0.15 vs 1.92±0.11,p=0.42);但GnRH激动剂组主要心脑血管事件发生率显著高于拮抗剂组(20% vs 3%,p=0.013),拮抗剂12个月绝对风险降低18.1%(95%CI 4.6-31.2,p=0.032)。

要点

  • 主要终点内皮功能两组无显著差异(反应性充血指数2.07±0.15 vs 1.92±0.11,p=0.42)。
  • GnRH激动剂组主要心脑血管事件20%,拮抗剂组3%(p=0.013)。
  • 拮抗剂12个月主要心脑血管事件绝对风险降低18.1%(95%CI 4.6-31.2,p=0.032)。

核心结论

  • 在合并心血管疾病的前列腺癌患者中,GnRH激动剂治疗者主要心脑血管事件显著多于GnRH拮抗剂治疗者。
  • 这些II期结果提示,对合并心血管疾病的前列腺癌患者选择雄激素剥夺治疗方式可能对心脏结局产生不同影响。

研究设计与样本

  • II期随机开放标签研究,纳入80例前列腺癌合并心血管疾病男性,随机接受GnRH激动剂或拮抗剂治疗1年。
  • GnRH拮抗剂组41例,GnRH激动剂组39例,两组基线特征相似。
  • 主要终点为用EndoPAT 2000设备测定的内皮功能,预设次要终点为新发心血管事件。

主要发现

  • 主要终点内皮功能两组无差异(平均±SD反应性充血指数2.07±0.15 vs 1.92±0.11,p=0.42)。
  • 试验期间15例发生新发心血管事件(次要终点),其中9例发生主要心脑血管事件,包括死亡2例、心肌梗死1例、脑血管事件2例、经皮血管成形术并冠状动脉支架置入4例。
  • 随机接受GnRH激动剂者20%发生主要心脑血管事件,GnRH拮抗剂者3%(p=0.013)。
  • 使用GnRH拮抗剂12个月主要心脑血管事件的绝对风险降低为18.1%(95%CI 4.6-31.2,p=0.032)。

临床怎么用

  • 作者认为,这些II期结果提示对合并心血管疾病的前列腺癌患者选择雄激素剥夺治疗方式可能对心脏结局产生不同影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy may increase the risk of cardiovascular disease. Limited data suggest that GnRH (gonadotropin-releasing hormone) antagonist may be associated with a lower risk of cardiovascular disease than GnRH agonist. MATERIALS AND METHODS: We performed a phase II, randomized, open label study in men with prostate cancer and preexisting cardiovascular disease who were randomized to receive GnRH agonists or antagonists for 1 year. The primary outcome was endothelial function measured by the EndoPAT 2000 device (Itamar Medical, Caesarea, Israel). The predefined secondary outcome was a new cardiovascular event. Patients were followed for the development of cardiovascular disease, defined as death, myocardial infarction, a cerebrovascular event, percutaneous angioplasty with coronary stent insertion or hospitalizations due to cardiac events. RESULTS: A total of 80 patients were enrolled in study, including 41 and 39 who received GnRH antagonist and agonist, respectively. Patients in each arm had similar baseline characteristics. We did not detect a difference in the primary end point (endothelial function) between the groups (mean ± SD reactive hyperemia index 2.07 ± 0.15 vs 1.92 ± 0.11, p=0.42). However, during the trial period a new cardiovascular event (the secondary end point) developed in 15 patients. Of cases new major cardiovascular and cerebrovascular events developed in 9, including death in 2, myocardial infarction in 1, a cerebrovascular event in 2 and percutaneous angioplasty with coronary stent insertion in 4. Of the patients 20% randomized to GnRH agonist experienced a major cardiovascular and cerebrovascular event compared to 3% of those on GnRH antagonist (p=0.013). The absolute risk reduction in major cardiovascular and cerebrovascular events at 12 months using GnRH antagonist was 18.1% (95% CI 4.6-31.2, p=0.032). CONCLUSIONS: To our knowledge this is the first prospective study to test cardiovascular outcomes among patients with prostate cancer who received androgen deprivation therapy. No differences in the primary end point were noted between the study arms. However, the secondary end point revealed that patients treated with GnRH agonist experienced significantly more major cardiovascular and cerebrovascular events than those treated with GnRH antagonist. These phase II results suggest that in patients with prostate cancer who have preexisting cardiovascular disease selecting the androgen deprivation therapy modality may differentially affect cardiac outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Margel D, Peer A, Ber Y, et al. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J Urol. 2019. PMID: 31188734. doi:10.1097/JU.0000000000000384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。